BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia

BioNexus Gene Lab Corp

BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
BGLC will receive 1.5 million common shares of BirchBioMed in exchange.
Collaboration to commercialize FS2 (kynurenic acid) topical cream in Malaysia and Singapore.
Term sheet non-binding except 60-day exclusivity; no assurance definitive agreement will be reached.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.